CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) |
Preferred stock
Series A Preferred Stock
|
Preferred stock
Series T Preferred Stock
|
Preferred stock
Series Seed Preferred Stock
|
Common Stock |
Additional Paid-in Capital |
Noncontrolling Interest |
Accumulated Deficit |
Total |
---|---|---|---|---|---|---|---|---|
Balance at the beginning at Dec. 31, 2023 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 6,971 | $ 82,005,447 | $ (13,251) | $ (44,637,430) | $ 45,338,794 |
Balance at the beginning (in shares) at Dec. 31, 2023 | 185,440,880 | 9,642,080 | 204,810,720 | 697,085,900 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Sale of Common Stock | $ 2 | 201,124 | 201,126 | |||||
Sale of Common Stock (in shares) | 177,980 | |||||||
Stock compensation expense | 2,666,169 | 2,666,169 | ||||||
Net income (loss) | (4,020,586) | (4,020,586) | ||||||
Balance at the end at Mar. 31, 2024 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 6,973 | 84,872,740 | (13,251) | (48,658,016) | 44,185,503 |
Balance at the end (in shares) at Mar. 31, 2024 | 185,440,880 | 9,642,080 | 204,810,720 | 697,263,880 | ||||
Balance at the beginning at Dec. 31, 2023 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 6,971 | 82,005,447 | (13,251) | (44,637,430) | $ 45,338,794 |
Balance at the beginning (in shares) at Dec. 31, 2023 | 185,440,880 | 9,642,080 | 204,810,720 | 697,085,900 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Sale of Common Stock (in shares) | 177,980 | |||||||
Offering Costs | $ 0 | |||||||
Net income (loss) | (7,042,730) | |||||||
Balance at the end at Jun. 30, 2024 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 6,979 | 87,540,794 | (13,251) | (51,680,160) | 43,831,419 |
Balance at the end (in shares) at Jun. 30, 2024 | 185,440,880 | 9,642,080 | 204,810,720 | 697,912,240 | ||||
Balance at the beginning at Mar. 31, 2024 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 6,973 | 84,872,740 | (13,251) | (48,658,016) | 44,185,503 |
Balance at the beginning (in shares) at Mar. 31, 2024 | 185,440,880 | 9,642,080 | 204,810,720 | 697,263,880 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Sale of Common Stock | 350 | 350 | ||||||
Exercise of stock options | $ 6 | 13,959 | 13,965 | |||||
Exercise of stock options (in shares) | 648,360 | |||||||
Stock compensation expense | 2,653,745 | 2,653,745 | ||||||
Net income (loss) | (3,022,144) | (3,022,144) | ||||||
Balance at the end at Jun. 30, 2024 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 6,979 | 87,540,794 | (13,251) | (51,680,160) | 43,831,419 |
Balance at the end (in shares) at Jun. 30, 2024 | 185,440,880 | 9,642,080 | 204,810,720 | 697,912,240 | ||||
Balance at the beginning at Dec. 31, 2024 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 7,028 | 95,543,998 | (13,251) | (61,174,088) | 42,340,744 |
Balance at the beginning (in shares) at Dec. 31, 2024 | 185,440,880 | 9,642,080 | 204,810,720 | 702,861,520 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Sale of Common Stock | $ 19 | 2,125,007 | 2,125,026 | |||||
Sale of Common Stock (in shares) | 1,922,194 | |||||||
Offering Costs | (1,444,755) | (1,444,755) | ||||||
Stock compensation expense | 2,651,080 | 2,651,080 | ||||||
Net income (loss) | 1,717,451 | 1,717,451 | ||||||
Balance at the end at Mar. 31, 2025 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 7,047 | 98,875,330 | (13,251) | (59,456,637) | 47,389,546 |
Balance at the end (in shares) at Mar. 31, 2025 | 185,440,880 | 9,642,080 | 204,810,720 | 704,783,714 | ||||
Balance at the beginning at Dec. 31, 2024 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 7,028 | 95,543,998 | (13,251) | (61,174,088) | $ 42,340,744 |
Balance at the beginning (in shares) at Dec. 31, 2024 | 185,440,880 | 9,642,080 | 204,810,720 | 702,861,520 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Sale of Common Stock (in shares) | 7,664,037 | |||||||
Offering Costs | $ (5,584,525) | |||||||
Net income (loss) | 4,995,352 | |||||||
Balance at the end at Jun. 30, 2025 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 7,286 | 103,673,693 | (13,251) | (56,178,736) | 55,466,049 |
Balance at the end (in shares) at Jun. 30, 2025 | 185,440,880 | 9,642,080 | 204,810,720 | 728,767,714 | ||||
Balance at the beginning at Mar. 31, 2025 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 7,047 | 98,875,330 | (13,251) | (59,456,637) | 47,389,546 |
Balance at the beginning (in shares) at Mar. 31, 2025 | 185,440,880 | 9,642,080 | 204,810,720 | 704,783,714 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Sale of Common Stock | $ 57 | 6,305,843 | 6,305,900 | |||||
Sale of Common Stock (in shares) | 5,741,843 | |||||||
Exercise of stock options | $ 182 | 105,852 | 106,034 | |||||
Exercise of stock options (in shares) | 18,242,157 | |||||||
Offering Costs | (4,139,770) | (4,139,770) | ||||||
Stock compensation expense | 2,526,438 | 2,526,438 | ||||||
Net income (loss) | 3,277,901 | 3,277,901 | ||||||
Balance at the end at Jun. 30, 2025 | $ 5,286,667 | $ 983,634 | $ 1,706,756 | $ 7,286 | $ 103,673,693 | $ (13,251) | $ (56,178,736) | $ 55,466,049 |
Balance at the end (in shares) at Jun. 30, 2025 | 185,440,880 | 9,642,080 | 204,810,720 | 728,767,714 |
X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|